We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Can Ligand's Captisol Deals Boost Growth in the Long Run?
Read MoreHide Full Article
On Aug 14, 2017, we issued an updated report on Ligand Pharmaceuticals Incorporated (LGND - Free Report) .
Ligand’s Captisol formulation technology platform has allowed it to enter into partnerships with several leading drug companies like Novartis AG (NVS - Free Report) , Merck & Co., Inc. (MRK - Free Report) and Amgen Inc. (AMGN - Free Report) , providing it with funds in the form of milestone and royalty payments. Royalties depend on the sales of its two key partnered assets – Novartis’ Kyprolis and Amgen’s Promacta.
Ligand receives royalties and milestone payments for several FDA-approved products that uses its Captisol technology. Latest product approvals include Spectrum’s Evomela, Lundbeck’s Carnexiv and Melinta Therapeutics’ Baxdela. Apart from these, several other candidates are in late-stage development and is expected to bring in royalties for the company once commercialized.
In July, the company announced that it has entered into another commercial license and supply agreement with Amgen, granting it with rights to use Captisol in the formulation of its anti-CD33 x anti-CD3 (BiTE) bispecific antibody, AMG 330. Under the agreement terms, Ligand is entitled to potential milestone payments, royalties and revenues from the future sales of AMG 330.
Regarding the company’s internal pipeline, various candidates are being developed for indications like diabetes. One of the most advanced candidates is LGD-6972, presently undergoing a phase II study for treatment of type II diabetes. Data from this trial is awaited in the second half of 2017 with potential to bring in future licensing opportunities.
Nonetheless, Ligand’s entry into the Medical Devices Segment with the acquisition of multiple programs owned by CorMatrix is also encouraging.
However, Ligand obtains Captisol from a single supplier, Hovione – a major global supplier of active pharmaceutical ingredients and drug product intermediates, located in Portugal. Any interruption in Captisol’s supply would hit the company’s results.
Zacks' 10-Minute Stock-Picking Secret
Since 1988, the Zacks system has more than doubled the S&P 500 with an average gain of +25% per year. With compounding, rebalancing, and exclusive of fees, it can turn thousands into millions of dollars.
But here's something even more remarkable: You can master this proven system without going to a single class or seminar. And then you can apply it to your portfolio in as little as 10 minutes a month.
Image: Bigstock
Can Ligand's Captisol Deals Boost Growth in the Long Run?
On Aug 14, 2017, we issued an updated report on Ligand Pharmaceuticals Incorporated (LGND - Free Report) .
Ligand’s Captisol formulation technology platform has allowed it to enter into partnerships with several leading drug companies like Novartis AG (NVS - Free Report) , Merck & Co., Inc. (MRK - Free Report) and Amgen Inc. (AMGN - Free Report) , providing it with funds in the form of milestone and royalty payments. Royalties depend on the sales of its two key partnered assets – Novartis’ Kyprolis and Amgen’s Promacta.
Ligand receives royalties and milestone payments for several FDA-approved products that uses its Captisol technology. Latest product approvals include Spectrum’s Evomela, Lundbeck’s Carnexiv and Melinta Therapeutics’ Baxdela. Apart from these, several other candidates are in late-stage development and is expected to bring in royalties for the company once commercialized.
In July, the company announced that it has entered into another commercial license and supply agreement with Amgen, granting it with rights to use Captisol in the formulation of its anti-CD33 x anti-CD3 (BiTE) bispecific antibody, AMG 330. Under the agreement terms, Ligand is entitled to potential milestone payments, royalties and revenues from the future sales of AMG 330.
Regarding the company’s internal pipeline, various candidates are being developed for indications like diabetes. One of the most advanced candidates is LGD-6972, presently undergoing a phase II study for treatment of type II diabetes. Data from this trial is awaited in the second half of 2017 with potential to bring in future licensing opportunities.
Nonetheless, Ligand’s entry into the Medical Devices Segment with the acquisition of multiple programs owned by CorMatrix is also encouraging.
However, Ligand obtains Captisol from a single supplier, Hovione – a major global supplier of active pharmaceutical ingredients and drug product intermediates, located in Portugal. Any interruption in Captisol’s supply would hit the company’s results.
Zacks' 10-Minute Stock-Picking Secret
Since 1988, the Zacks system has more than doubled the S&P 500 with an average gain of +25% per year. With compounding, rebalancing, and exclusive of fees, it can turn thousands into millions of dollars.
But here's something even more remarkable: You can master this proven system without going to a single class or seminar. And then you can apply it to your portfolio in as little as 10 minutes a month.
Learn the secret >>